We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is reviewing significantly higher numbers of generic drugs under its Competitive Generic Therapy (CGT) pathway, the latest quarterly report on the agency’s GDUFA II performance reveals. Read More
The FDA has granted accelerated approval to GlaxoSmithKline’s monoclonal antibody Jemperli (dostarlimab) for treating women with recurrent or advanced endometrial cancer. Read More
The FDA gave the drug a breakthrough status based on results of a phase 2 study showing the drug plus chemotherapy significantly improved survival for patients. Read More
The FDA’s latest quarterly snapshot of the agency’s GDUFA II performance shows fewer abbreviated new drug applications (ANDAs) under review than for the same time last year and that the agency is taking much longer to issue tentative approvals. Read More
As global criminals step up efforts to exploit the pandemic, Pfizer is combating the sale of counterfeit versions of its COVID-19 vaccines in Mexico and Poland. Read More
The FDA has granted priority reviews for two supplemental Biologics License Applications (sBLAs) by Seagen and Astellas Pharma for Padcev, their antibody-drug conjugate therapy for treating bladder cancer. Read More
In addition to its pact with GSK, CureVac has also partnered with Novartis and Bayer to potentially manufacture hundreds of millions of doses of CVnCoV. Read More
The FDA has approved Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) in combination with chemotherapy as a first-line treatment for patients with gastric and esophageal cancers. Read More